4
Participants
Start Date
January 26, 2017
Primary Completion Date
May 17, 2017
Study Completion Date
June 2, 2017
BIM23B065
Subcutaneous twice a day or three times a day administration of BIM23B065. Dose will be 0.4, 0.6, 0.8 or 1 mg (twice a day or three times a day).
Medical Centre, University of Pecs, I Department of Internal Medicine, Pécs
Clinical Center of Serbia, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Belgrade
Vinnitsa Regional Endocrinology Dispensary, Vinnitsa National Medical University named after M.I Pirogov, Therapeutic Department № 2, Vinnitsa
"Institute of Endocrinological Pathology named after Danilevskij V.Ya., AMS of Ukraine, Department of General Endocrinology", Kharkiv
CHU de Liège, University of Liège, Domaine Universitaire du Sart-Tilman, Liège
"Institute of Endocrinology and Metabolism named after V.P.Komisarenko, AMS Ukraine, Department of General Endocrinology", Kiev
Lead Sponsor
Ipsen
INDUSTRY